– an award that recognizes significant innovation in science, the team has now received a Medical Futures innovation Award for the product.ZIOPHARM Receives Orphan Medicinal Product Designation for Palifosfamide in the treatment of soft tissue sarcomaZIOPHARM Oncology , announced today that the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion about ZIOPHARM application for orphan medicinal product designation for the treatment of soft tissue sarcoma Palifosfamide .

– There is a significant unmet need for additional treatments for soft tissue sarcomas than locally effective operation to address, said Jonathan Lewis, and Chief Executive and Medical Officer of ZIOPHARM. We look forward, as soon orphan drug status in Europe, which received orphan drug designation in the United States this year we expand our inpatient treatment in phase II randomized controlled trial in STS initiate.They analyzed paste the test features:DNA amplification method gestational age type of sample Y chromosome acid sequence Release Date They found a gender and amplification technique had been the most impact on the performance of the test.